COVID-19 infection in patients with chronic myeloid leukemia in the Orenburg region during the SARS-CoV-2 pandemic

Background. Oncohematological patients are more predispose to SARS-CoV-2 infection than healthy individuals and patients with malignant neoplasms, and also they have a worse prognosis, which is because of immune system disorders, both due to the underlying disease and as a result of immunosuppressiv...

Full description

Saved in:
Bibliographic Details
Main Authors: G. B. Kuchma, U. A. Yakubova, L. K. Kozlova, S. A. Lebedenko, F. R. Sayfutdinov
Format: Article
Language:Russian
Published: ABV-press 2022-07-01
Series:Онкогематология
Subjects:
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/566
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850024634588594176
author G. B. Kuchma
U. A. Yakubova
L. K. Kozlova
S. A. Lebedenko
F. R. Sayfutdinov
author_facet G. B. Kuchma
U. A. Yakubova
L. K. Kozlova
S. A. Lebedenko
F. R. Sayfutdinov
author_sort G. B. Kuchma
collection DOAJ
description Background. Oncohematological patients are more predispose to SARS-CoV-2 infection than healthy individuals and patients with malignant neoplasms, and also they have a worse prognosis, which is because of immune system disorders, both due to the underlying disease and as a result of immunosuppressive therapy. There is limited data regarding the impact of SARS-CoV-2 infection on the survival of patients with chronic myeloid leukemia (CML).Aim. To evaluate the course and outcome of COVID-19 in patients with CML in the Orenburg region during the SARS-CoV-2 pandemic.Materials and methods. All 166 patients with CML over 18 years of age were analyzed during the COVID-19 pandemic between february 2020 and December 2021. The source of information was data from the personalized register of patients with CML and the unified state health information system.Results. The proportion of SARS-CoV-2 infection among patients with CML was 36 %. The risk of infection was not affected by age, gender, work features, place of residence, phase or duration of the disease, and therapy. underwent COVID-19 patients were 1.6 times more likely to be overweight and 2 times more likely to have a second cancer. A significant increase in the number of outpatient visits to polyclinics and number of hospital admissions during the pandemic was revealed in the group of patients who had SARS-CoV-2 infection. underwent COVID-19 patients were over 60 years of age in 48.3 % of cases and had one or more comorbidities in 77.6 % cases. SARS-CoV-2-infected patients with CML had a favorable outcome: a mild course of infection in 75.9 % of cases and a low mortality rate - 6.8 % (4 of 58 patients) were observed. COVID-19 was recognized as the cause of death in only 2 patients with optimal molecular response and comorbidity. In two other patients who underwent COVID-19, the progression of CML to a blast crisis was recognized as the cause of death. There were no significant differences in mortality level in the group of patients who had SARS-CoV-2 infection and those who did not have COVID-19.Conclusion. patients with CML living in the Orenburg region have a low susceptibility to SARS-CoV-2 infection and a mild course of the disease. The mortality rate for CML patients infected with SARS-CoV-2 was 6.8 %. unfavorable factors in the overall survival of patients with CML infected with SARS-CoV-2 were high comorbidity and blast crisis. Reducing the number of outpatient visits during the pandemic and using remote medical consultations is likely to reduce the risk of SARS-CoV-2 infection.
format Article
id doaj-art-d2b58e461d6f460284a16a19218b85e4
institution DOAJ
issn 1818-8346
2413-4023
language Russian
publishDate 2022-07-01
publisher ABV-press
record_format Article
series Онкогематология
spelling doaj-art-d2b58e461d6f460284a16a19218b85e42025-08-20T03:01:03ZrusABV-pressОнкогематология1818-83462413-40232022-07-0117311912610.17650/1818-8346-2022-17-3-119-126459COVID-19 infection in patients with chronic myeloid leukemia in the Orenburg region during the SARS-CoV-2 pandemicG. B. Kuchma0U. A. Yakubova1L. K. Kozlova2S. A. Lebedenko3F. R. Sayfutdinov4Orenburg State Medical University, Ministry of Health of RussiaOrenburg State Medical University, Ministry of Health of RussiaOrenburg State Medical University, Ministry of Health of RussiaOrenburg Regional Clinical HospitalOrenburg State Medical University, Ministry of Health of RussiaBackground. Oncohematological patients are more predispose to SARS-CoV-2 infection than healthy individuals and patients with malignant neoplasms, and also they have a worse prognosis, which is because of immune system disorders, both due to the underlying disease and as a result of immunosuppressive therapy. There is limited data regarding the impact of SARS-CoV-2 infection on the survival of patients with chronic myeloid leukemia (CML).Aim. To evaluate the course and outcome of COVID-19 in patients with CML in the Orenburg region during the SARS-CoV-2 pandemic.Materials and methods. All 166 patients with CML over 18 years of age were analyzed during the COVID-19 pandemic between february 2020 and December 2021. The source of information was data from the personalized register of patients with CML and the unified state health information system.Results. The proportion of SARS-CoV-2 infection among patients with CML was 36 %. The risk of infection was not affected by age, gender, work features, place of residence, phase or duration of the disease, and therapy. underwent COVID-19 patients were 1.6 times more likely to be overweight and 2 times more likely to have a second cancer. A significant increase in the number of outpatient visits to polyclinics and number of hospital admissions during the pandemic was revealed in the group of patients who had SARS-CoV-2 infection. underwent COVID-19 patients were over 60 years of age in 48.3 % of cases and had one or more comorbidities in 77.6 % cases. SARS-CoV-2-infected patients with CML had a favorable outcome: a mild course of infection in 75.9 % of cases and a low mortality rate - 6.8 % (4 of 58 patients) were observed. COVID-19 was recognized as the cause of death in only 2 patients with optimal molecular response and comorbidity. In two other patients who underwent COVID-19, the progression of CML to a blast crisis was recognized as the cause of death. There were no significant differences in mortality level in the group of patients who had SARS-CoV-2 infection and those who did not have COVID-19.Conclusion. patients with CML living in the Orenburg region have a low susceptibility to SARS-CoV-2 infection and a mild course of the disease. The mortality rate for CML patients infected with SARS-CoV-2 was 6.8 %. unfavorable factors in the overall survival of patients with CML infected with SARS-CoV-2 were high comorbidity and blast crisis. Reducing the number of outpatient visits during the pandemic and using remote medical consultations is likely to reduce the risk of SARS-CoV-2 infection.https://oncohematology.abvpress.ru/ongm/article/view/566chronic myeloid leukemiatyrosine kinase inhibitorcovid-19mortality
spellingShingle G. B. Kuchma
U. A. Yakubova
L. K. Kozlova
S. A. Lebedenko
F. R. Sayfutdinov
COVID-19 infection in patients with chronic myeloid leukemia in the Orenburg region during the SARS-CoV-2 pandemic
Онкогематология
chronic myeloid leukemia
tyrosine kinase inhibitor
covid-19
mortality
title COVID-19 infection in patients with chronic myeloid leukemia in the Orenburg region during the SARS-CoV-2 pandemic
title_full COVID-19 infection in patients with chronic myeloid leukemia in the Orenburg region during the SARS-CoV-2 pandemic
title_fullStr COVID-19 infection in patients with chronic myeloid leukemia in the Orenburg region during the SARS-CoV-2 pandemic
title_full_unstemmed COVID-19 infection in patients with chronic myeloid leukemia in the Orenburg region during the SARS-CoV-2 pandemic
title_short COVID-19 infection in patients with chronic myeloid leukemia in the Orenburg region during the SARS-CoV-2 pandemic
title_sort covid 19 infection in patients with chronic myeloid leukemia in the orenburg region during the sars cov 2 pandemic
topic chronic myeloid leukemia
tyrosine kinase inhibitor
covid-19
mortality
url https://oncohematology.abvpress.ru/ongm/article/view/566
work_keys_str_mv AT gbkuchma covid19infectioninpatientswithchronicmyeloidleukemiaintheorenburgregionduringthesarscov2pandemic
AT uayakubova covid19infectioninpatientswithchronicmyeloidleukemiaintheorenburgregionduringthesarscov2pandemic
AT lkkozlova covid19infectioninpatientswithchronicmyeloidleukemiaintheorenburgregionduringthesarscov2pandemic
AT salebedenko covid19infectioninpatientswithchronicmyeloidleukemiaintheorenburgregionduringthesarscov2pandemic
AT frsayfutdinov covid19infectioninpatientswithchronicmyeloidleukemiaintheorenburgregionduringthesarscov2pandemic